Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jet2 launches £250m share buyback, delivers solid Q1 trading performance

(Sharecast News) - Leisure travel group Jet2 announced a £250.0m share buyback on Tuesday as it outlined a solid FY25 trading performance despite uncertainty across the wider travel sector. Jet2 said it expects to report a profit before foreign exchange revaluation and taxation of between £565.0m and £570.0m for the year ended 31 March, excluding £10.0m of profit on the disposal of assets, primarily from its retired Boeing 757-200 aircraft fleet.

"This represents another year of healthy profit growth, up approximately 9% on the prior year and is in line with current market expectations," said Jet2.

The London-listed firm also said that notwithstanding the early repayment of its £387.4m convertible bond during the year, its balance sheet position "remains strong", with total cash of £3.2bn at the end of FY25 and an 'Own Cash' balance of £1.1bn.

As a result of its "sustainable cash generative business model and strong balance sheet", Jet2 now intends to launch an on-market share buyback programme of up to £250.0m. It then expects to cancel those shares upon buyback, providing a positive enhancement to earnings per share.

Looking ahead, Jet2 stated "on sale capacity" for summer 2025 was currently 8.3% higher than summer 2024 at 18.6m seats, with its new bases at Bournemouth and London Luton airports contributing approximately 4% of this growth.

As of 0915 BST, Jet2 shares had surged 15.87% to 1,564.18p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.